COMBINED ADMINISTRATION OF CYSTEINE-ASPARTIC PROTEASE INHIBITORS WITH P2Y12 RECEPTOR ANTAGONISTS PROTECTS THE HEART AGAINST MYOCARDIAL INFARCTION

摘要

: The present disclosure generally pertains to methods of treating myocardialinfarct involving administering a plateletanti-aggregate, a cysteine-aspartic protease inhibitor, and reperfusiontherapy. In certain embodiments, the platelet anti-aggregate isat least one P2Y12 receptor antagonist or Glycoprotein Ilb/IIIa inhibitor, thecysteine-aspartic protease inhibitor is selected from thegroup consisting of Caspase-1, 4, 5, 11 and 12 inhibitors, and reperfusiontherapy is percutaneous coronary intervention. In certainembodiments, the at least one P2Y12 receptor antagonist is selected from thegroup consisting of cangrelor, ticagrelor, clopidogreland prasugrel. The disclosed methods provide an improved cardioprotectiveeffect against infarction when compared with the currentstandard of care.